Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy's Laboratories share price remains in focus on Thursday post Q1 results that were declared after the market hours on ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

Brokerages on Dr Reddy's Q1 results: Pharmaceutical major Dr Reddy’s Laboratories’ June quarter (Q1FY26) results received a ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global ...

Pharma major Dr. Reddy's Laboratories reported a marginal 2% year-on-year (YoY) growth in its consolidated net profit at Rs 1 ...

Best case scenario, Semaglutide can garner $500 million sales in FY27, HSBC said. It added that Dr Reddy's will be among the ...

Pharmaceutical major Dr. Reddys Laboratories reported its financial results for the first quarter (Q1) of FY26 on Thursday, ...